Objectives:Chronic heart failure is an important health problem that limits the daily life,quality of life,effort capacity and physiological condition of the patients. In subset of these patients symptoms persist despite optimal medical management. Enhanced External Counterpulsation (EECP) is a non-invasive Food and Drug Administration approved therapy which improves symptoms and clinical outcomes in patients with heart failure. However, there is limited data in Turkish cohort. In this study, we investigated the clinical effects of EECP on multiple paramaters associated with quality of life, funcional effort capacity and physiological status in Turkish patients with symptomatic chronic heart failure.
Methods: 21 individuals who were diagnosed with symptomatic chronic heart failure (left ventricular ejection fraction ≤40 %) with NYHA II-III were enrolled in the study. Eligible patients were assigned to 35 -session EECP treatment. NYHA classification, SF 36 quality of life quastionaire, Minnesota living heart failure quastionaire, quality of life index cardiac version IV and Beck depression scale were assessed and 6 minute walk test was performed before and after EECP treatment.
Results: The mean age of the patients was 57.4 ± 12.5 years. Patients underwent an EECP treatment course of 35 hours with an exellent compliance rate. EECP therapy resulted in significant improvement in NYHA functional class, quality of life index, effort capacity and pyhsiological condition in all patients without any adverse event (p = 0,001) (Table 1).
Conclusion: EECP treatment significantly improved clinical parameters and effort capacity in patients with symptomatic heart failure. These results suggest that EECP is an effective and a safe therapy in Class II-III heart failure patients whose symptoms persist despite optimal medical management.